<DOC>
	<DOC>NCT02969044</DOC>
	<brief_summary>This is an 8 week study to assess the efficacy and safety profile of PF-06651600 in seropositive subjects with rheumatoid arthritis with an inadequate response to methotrexate (up to approximately 50% of subjects may also have had an inadequate response to 1 anti-TNF biologic).</brief_summary>
	<brief_title>Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Inclusion Criteria Subjects between the ages of 18 and 75 years, inclusive Must have moderatetosevere, active Rheumatoid Arthritis Must have had an inadequate response to Methotrexate Subjects may have received one approved TNF inhibiting biologic agent that was inadequately effective and/or not tolerated Exclusion Criteria Subjects with any acute or chronic infections or infection history Have acute or active chronic dermatological disorders prior to study start Any major illness/condition(s) or evidence of an unstable clinical condition that in the judgment of the investigator would make the subject inappropriate for entry into this study Known immunodeficiency disorder or a first degree relative with hereditary immunodeficiency Any live (attenuated) vaccines or current routine household contact with anyone who has received live (attenuated) vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>